Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Minerva Neuroscie
(NQ:
NERV
)
2.660
-0.060 (-2.21%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Minerva Neuroscie
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 06, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
May 01, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
February 27, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Inc. (NASDAQ: NERV) Near the Top of Equities by Percentage Gain on 6/28
June 28, 2023
Via
Investor Brand Network
Minerva Neurosciences Inc. (NASDAQ: NERV) Leading the Way in Monday Trading Based on Percentage Gain
May 01, 2023
Via
Investor Brand Network
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
February 22, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
November 07, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
August 01, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
June 28, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023
Company to host conference call today at 8:30 a.m. ET
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 10, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
May 08, 2023
Management to Host Conference Call
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 01, 2023
FDA grants appeal and files NDA
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 08, 2023
Company to Host Conference Call Today at 8:30 a.m. ET
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
March 01, 2023
Management to Host Conference Call
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
December 28, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022
Company To Host Live Webcast Today at 8:30 a.m. ET
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 02, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
October 17, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
5 Best Performing Micro-Cap Stocks Through the First Half of 2022
July 05, 2022
The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices
Via
Spotlight Growth
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.